De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

LifeTech Scientific Inkomsten in het verleden

Verleden criteriumcontroles 1/6

LifeTech Scientific is de winst gegroeid met een gemiddeld jaarlijks percentage van 14.1%, terwijl de Medical Equipment industrie de winst jaarlijks groeide met 14.7%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 17% per jaar. Het rendement op eigen vermogen van LifeTech Scientific is 2.4%, en het heeft een nettomarge van 19.4%.

Belangrijke informatie

14.1%

Groei van de winst

13.8%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	13.7%
Inkomstengroei	17.0%
Rendement op eigen vermogen	2.4%
Nettomarge	19.4%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear

Apr 25

Recent updates

Some Confidence Is Lacking In LifeTech Scientific Corporation's (HKG:1302) P/E

Jul 05

LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear

Apr 25

What LifeTech Scientific Corporation's (HKG:1302) P/E Is Not Telling You

Dec 25

Returns On Capital At LifeTech Scientific (HKG:1302) Have Stalled

Nov 28

At HK$2.37, Is LifeTech Scientific Corporation (HKG:1302) Worth Looking At Closely?

Nov 03

Here's What To Make Of LifeTech Scientific's (HKG:1302) Decelerating Rates Of Return

Oct 14

There's Been No Shortage Of Growth Recently For LifeTech Scientific's (HKG:1302) Returns On Capital

Jul 15

Does LifeTech Scientific (HKG:1302) Deserve A Spot On Your Watchlist?

Jun 30

A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)

Jun 15

Returns At LifeTech Scientific (HKG:1302) Are On The Way Up

Apr 03

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

Mar 15

Is LifeTech Scientific Corporation (HKG:1302) Potentially Undervalued?

Jan 22

Some Investors May Be Worried About LifeTech Scientific's (HKG:1302) Returns On Capital

Dec 19

Here's Why I Think LifeTech Scientific (HKG:1302) Might Deserve Your Attention Today

Dec 06

Is LifeTech Scientific (HKG:1302) A Risky Investment?

Nov 20

An Intrinsic Calculation For LifeTech Scientific Corporation (HKG:1302) Suggests It's 34% Undervalued

Oct 12

The Returns On Capital At LifeTech Scientific (HKG:1302) Don't Inspire Confidence

Sep 13

Should You Be Adding LifeTech Scientific (HKG:1302) To Your Watchlist Today?

Aug 28

What Is LifeTech Scientific Corporation's (HKG:1302) Share Price Doing?

Aug 13

LifeTech Scientific's (HKG:1302) Returns On Capital Not Reflecting Well On The Business

Jun 08

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

May 26

Should You Investigate LifeTech Scientific Corporation (HKG:1302) At HK$4.14?

May 11

LifeTech Scientific (HKG:1302) Could Easily Take On More Debt

Mar 31

Shareholders Are Thrilled That The LifeTech Scientific (HKG:1302) Share Price Increased 274%

Feb 21

Do Insiders Own Lots Of Shares In LifeTech Scientific Corporation (HKG:1302)?

Jan 26

Does LifeTech Scientific's (HKG:1302) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 13

Are Strong Financial Prospects The Force That Is Driving The Momentum In LifeTech Scientific Corporation's HKG:1302) Stock?

Nov 25

Opbrengsten en kosten

Hoe LifeTech Scientific geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

SEHK:1302 Opbrengsten, kosten en inkomsten (CNY Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	1,281	249	459	327
31 Mar 24	1,274	256	437	313
31 Dec 23	1,267	263	415	298
30 Sep 23	1,224	297	399	258
30 Jun 23	1,182	331	382	219
31 Mar 23	1,139	328	365	214
31 Dec 22	1,097	325	348	208
30 Sep 22	1,058	314	329	195
30 Jun 22	1,019	303	311	181
31 Mar 22	972	298	297	164
31 Dec 21	925	292	283	146
30 Sep 21	878	307	320	164
30 Jun 21	830	322	356	183
31 Mar 21	736	269	342	175
31 Dec 20	642	216	327	167
30 Sep 20	638	176	302	150
30 Jun 20	633	136	277	133
31 Mar 20	651	132	288	137
31 Dec 19	669	129	299	141
30 Sep 19	644	138	276	137
30 Jun 19	618	146	252	132
31 Mar 19	588	134	239	124
31 Dec 18	557	121	226	115
30 Sep 18	518	134	196	96
30 Jun 18	480	147	165	76
31 Mar 18	445	155	151	69
31 Dec 17	409	163	138	62
30 Sep 17	391	171	138	61
30 Jun 17	373	178	139	59
31 Mar 17	363	162	136	58
31 Dec 16	353	146	133	58
30 Sep 16	336	201	126	55
30 Jun 16	319	256	119	52
31 Mar 16	315	129	120	50
31 Dec 15	312	2	121	47
30 Sep 15	304	-41	123	42
30 Jun 15	296	-84	125	38
31 Mar 15	289	-83	135	35
31 Dec 14	283	-81	145	33
30 Sep 14	280	-151	151	35
30 Jun 14	258	-209	139	34
31 Mar 14	248	-89	130	33
31 Dec 13	231	-66	115	31

Kwaliteitswinsten: 1302 heeft een grote eenmalige verlies van CN¥139.3M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th June, 2024.

Groeiende winstmarge: De huidige netto winstmarges (19.4%) 1302 } zijn lager dan vorig jaar (28%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van 1302 is de afgelopen 5 jaar met 14.1% per jaar gegroeid.

Versnelling van de groei: De winstgroei 1302 is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: 1302 had het afgelopen jaar een negatieve winstgroei ( -24.8% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Medical Equipment ( -4.3% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 2.4% ) van 1302 wordt als laag beschouwd.

LifeTech Scientific Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First half 2024 earnings released: EPS: CN¥0.046 (vs CN¥0.049 in 1H 2023)

LifeTech Scientific Corporation to Report First Half, 2024 Results on Aug 30, 2024

LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear

Full year 2023 earnings released: EPS: CN¥0.06 (vs CN¥0.077 in FY 2022)

LifeTech Scientific Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: CN¥0.049 (vs CN¥0.05 in 1H 2022)

Recent updates

Investor sentiment improves as stock rises 18%

First half 2024 earnings released: EPS: CN¥0.046 (vs CN¥0.049 in 1H 2023)

New minor risk - Profit margin trend

LifeTech Scientific Corporation to Report First Half, 2024 Results on Aug 30, 2024

Some Confidence Is Lacking In LifeTech Scientific Corporation's (HKG:1302) P/E

LifeTech Scientific Corporation Announces One-Year Follow-Up Results of Phase II Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System

LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear

LifeTech Scientific Corporation, Annual General Meeting, May 27, 2024

Full year 2023 earnings released: EPS: CN¥0.06 (vs CN¥0.077 in FY 2022)

LifeTech Scientific Corporation to Report Fiscal Year 2023 Results on Mar 28, 2024

What LifeTech Scientific Corporation's (HKG:1302) P/E Is Not Telling You

Returns On Capital At LifeTech Scientific (HKG:1302) Have Stalled

At HK$2.37, Is LifeTech Scientific Corporation (HKG:1302) Worth Looking At Closely?

First half 2023 earnings released: EPS: CN¥0.049 (vs CN¥0.05 in 1H 2022)

Epione Surgical Navigation System Obtained Official Registration Approval by the China NMPA

Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)

LifeTech Scientific Corporation to Report First Half, 2023 Results on Aug 30, 2023

Is There Now An Opportunity In LifeTech Scientific Corporation (HKG:1302)?

Lifetech Scientific Corporation Announces Enrollment in the Phase Iii Clinical Study of Ibs®? Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed

Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)

Full year 2022 earnings released: EPS: CN¥0.077 (vs CN¥0.068 in FY 2021)

Investor sentiment improved over the past week

LifeTech Scientific Corporation Announces Enrollment in the China Randomized Controlled Clinical Study of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed

Insufficient new directors

Here's What To Make Of LifeTech Scientific's (HKG:1302) Decelerating Rates Of Return

LifeTech Scientific Corporation Announces FDA Approval Investigator-Initiated Pre-Market Clinical Trial of Lambre Plus Laa Closure System Obtained Medical Insurance Coverage in the US

First half 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.047 in 1H 2021)

LifeTech Scientific Corporation to Report Q2, 2022 Results on Aug 30, 2022

There's Been No Shortage Of Growth Recently For LifeTech Scientific's (HKG:1302) Returns On Capital

Does LifeTech Scientific (HKG:1302) Deserve A Spot On Your Watchlist?

A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)

Insufficient new directors

Returns At LifeTech Scientific (HKG:1302) Are On The Way Up

Full year 2021 earnings: EPS and revenues miss analyst expectations

LifeTech Scientific Corporation, Annual General Meeting, May 27, 2022

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

Is LifeTech Scientific Corporation (HKG:1302) Potentially Undervalued?

Some Investors May Be Worried About LifeTech Scientific's (HKG:1302) Returns On Capital

Here's Why I Think LifeTech Scientific (HKG:1302) Might Deserve Your Attention Today

Lifetech Scientific Corporation Announces YuranosTM Abdominal Aortic Stent Graft System Obtained Registration Approval from the China NMPA

Is LifeTech Scientific (HKG:1302) A Risky Investment?

An Intrinsic Calculation For LifeTech Scientific Corporation (HKG:1302) Suggests It's 34% Undervalued

The Returns On Capital At LifeTech Scientific (HKG:1302) Don't Inspire Confidence

First half 2021 earnings released: EPS CN¥0.047 (vs CN¥0.023 in 1H 2020)

Should You Be Adding LifeTech Scientific (HKG:1302) To Your Watchlist Today?

What Is LifeTech Scientific Corporation's (HKG:1302) Share Price Doing?

Investor sentiment deteriorated over the past week

LifeTech Scientific Corporation Announces Grant of Medical Device Registration Certificate in Malaysia for Its Self-Developed Ibs Angeltm Iron Bioresorbable Scaffold System

LifeTech Scientific's (HKG:1302) Returns On Capital Not Reflecting Well On The Business

Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock

Should You Investigate LifeTech Scientific Corporation (HKG:1302) At HK$4.14?

Investor sentiment improved over the past week

Non-Executive Director has left the company

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.031 in FY 2019)

LifeTech Scientific (HKG:1302) Could Easily Take On More Debt

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.031 in FY 2019)

LifeTech Scientific Corporation to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day low: HK$3.62

Shareholders Are Thrilled That The LifeTech Scientific (HKG:1302) Share Price Increased 274%

Lifetech Scientific Corporation Announces Admission to Special Examination and Approval Procedure for Innovative Medical Devices in Respect of Artery Stent Graft System

Do Insiders Own Lots Of Shares In LifeTech Scientific Corporation (HKG:1302)?

New 90-day high: HK$5.46

New 90-day high: HK$4.43

Does LifeTech Scientific's (HKG:1302) Statutory Profit Adequately Reflect Its Underlying Profit?

Are Strong Financial Prospects The Force That Is Driving The Momentum In LifeTech Scientific Corporation's HKG:1302) Stock?

Gl Trade Investment III L.P. and Gao Ling Fund, L.P., a fund managed by Hillhouse Capital Management, Ltd. acquired 10.67% stake in LifeTech Scientific Corporation (SEHK:1302) from Central Huijin Investment Ltd.

Market bids up stock over the past week

New 90-day high: HK$2.99

Market bids up stock over the past week